派林生物：公司控股股东及实控人将发生变更，中国生物将成为控股股东，中国医药集团将成为实际控制人

Core Viewpoint - Recently, Palin Bio announced that it has disclosed a relevant acquisition agreement and a notice of intended change in control, where China National Pharmaceutical Group Corporation will become the controlling shareholder of the company [1] Group 1: Acquisition Details - China National Pharmaceutical Group Corporation signed a "Framework Agreement for Acquisition" with the company's controlling shareholder, Qiongcheng Shengbang Yinghao Investment Partnership (Limited Partnership) [1] - Shengbang Yinghao intends to transfer its 21.03% stake in the company to China National Pharmaceutical [1] - A supplementary agreement to the "Share Transfer Agreement" has been signed recently by both parties [1] Group 2: Control Change Implications - If the equity change is implemented and completed, the company's controlling shareholder and actual controller will change [1] - China National Pharmaceutical will become the controlling shareholder, while China National Pharmaceutical Group Corporation will become the actual controller of the company [1]